4-[3-(nitrooxy)propoxy]benzoic acid | 1144618-41-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[3-(nitrooxy)propoxy]benzoic acid
• 英文别名: 4-(3-nitrooxypropoxy)benzoic acid
• CAS: 1144618-41-6
• 化学式: C₁₀H₁₁NO₆
• 分子量: 241.2
• InChiKey: ZNBOBRMSFZORFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[3-(nitrooxy)propoxy]benzoic acid 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 1.0h， 生成 3-methyl-1-phenyl-1H-pyrazol-5-yl 4-[3-(nitrooxy)propoxy]benzoate
  参考文献：
  名称：

  Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs

  摘要：

  A new class of co-drugs were synthesised by joining antioxidant edaravone with a vasodilating substructure containing NO-donor nitrooxy functions, and characterised for their stability in different media, lipophilicity and permeability profile. The products display good stability in water/co-solvent at different pH. Conversely, they are rapidly metabolised into edaravone and NO-donor moieties when incubated in human serum or rat-liver homogenates. In the latter conditions time dependent production of nitrite/nitrate (NOx) occurs. The compounds display wide-ranging lipophilicity. PAMPA studies predict good gastrointestinal absorption for a number of these compounds. The title products are potentially useful for treating ROS-related conditions accompanied by decreased NO availability. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.065
• 作为产物：
  描述：

  对羟基苯甲醛 在 potassium permanganate 、 potassium carbonate 、 silver nitrate 作用下， 以 丙酮 、 乙腈 为溶剂， 反应 13.0h， 生成 4-[3-(nitrooxy)propoxy]benzoic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide as potential antiplatelet agents

  摘要：

  A series of novel nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide were designed, synthesized and evaluated as potential antiplatelet agents. Compound 10b significantly inhibited the adenosine diphosphate (ADP)-induced platelet aggregation in vitro, superior to 6-amino-3-n-butylphthalide, 3-n-butylphthalide (NBP) and ticlopidine. Meanwhile 10b released moderate levels of NO, which could be beneficial for improving cardiovascular and cerebral circulation. Furthermore, 10b had an enhanced aqueous solubility relative to NBP. These findings may provide new insights into the development of novel antiplatelet agents for the treatment of thrombosis-related ischemic stroke. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.035

文献信息

• NEW NO-DONOR ASPIRIN DERIVATIVES
  申请人：Fruttero Roberta

  公开号：US20100210694A1

  公开（公告）日：2010-08-19

  The present invention refers to new NO-donors aspirin derivatives, a process for their preparation and pharmaceutical compositions containing them.

  本发明涉及一种新的NO供体阿司匹林衍生物，其制备方法和包含它们的药物组合物。
• [EN] NEW NO-DONOR ASPIRIN DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'ASPIRINE DONNEURS NO
  申请人：NICOX SA

  公开号：WO2009049961A3

  公开（公告）日：2009-06-25
• (Nitrooxyacyloxy)methyl Esters of Aspirin as Novel Nitric Oxide Releasing Aspirins
  作者：Loretta Lazzarato、Monica Donnola、Barbara Rolando、Konstantin Chegaev、Elisabetta Marini、Clara Cena、Antonella Di Stilo、Roberta Fruttero、Stefano Biondi、Ennio Ongini、Alberto Gasco

  DOI：10.1021/jm900587h

  日期：2009.8.27

  A series of (nitrooxyacyloxy)methyl esters of aspirin were synthesized and evaluated as new NO-donor aspirins. Different amounts of aspirin were released in serum from these products according to the nature of nitrooxyacyloxy moiety present, In the aromatic series, there is a rather good linear correlation between the amount of aspirin released and the potencies of the products in inhibiting platelet aggregation induced by collagen. Both the native compounds and the related nitrooxy-substituted acid metabolites were able to relax rat aorta strips precontracted with phenylephrine, in keeping with a NO-induced activation or the sGC as a mechanism that underlies the vasodilator effect. The products here described are new improved examples of NO-donor aspirins containing nitrooxy groups. They could represent all alternative to the use of aspirin ill a variety of clinical applications.
• Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins
  作者：Elena Gazzano、Konstantin Chegaev、Barbara Rolando、Marco Blangetti、Lorenzo Annaratone、Dario Ghigo、Roberta Fruttero、Chiara Riganti

  DOI：10.1016/j.bmc.2016.01.021

  日期：2016.3

  A library of nitric oxide-donor doxorubicins (NO-DOXOs) was synthesized by linking appropriate NO-donor moieties at C-14 position through an ester bridge. Their hydrolytic stability was evaluated. The intracellular accumulation and cytotoxicity of these novel NO-DOXOs were studied in DOXO-sensitive (HT29) and DOXO-resistant (HT29/dx) tumor-cells. Hydrolytically-stable compounds accumulated in HT29 and HT29/dx cells, thanks to the nitration of plasma-membrane efflux transporters. Surprisingly, no close correlation was found between intracellular accumulation and cytotoxicity. Only compounds with high mitochondria retention (due to nitration of mitochondrial efflux transporter) exert high cytotoxicity, through the activation of a mitochondrial-dependent apoptosis. (C) 2016 Elsevier Ltd. All rights reserved.